Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2011, Article ID 960267, 4 pages
http://dx.doi.org/10.1093/ecam/nen052
Original Article

Comparative Analysis of Viperidae Venoms Antibacterial Profile: a Short Communication for Proteomics

1Departamento de Biologia Celular e Molecular, Laboratório de Antibióticos, Bioquímica e Modelagem Molecular (LABioMol), Instituto de Biologia, CEG, Universidade Federal Fluminense, CEP 24001–970, Niterói, Brazil
2Cursos de Pós-graduação em Neuroimunologia - IB, e Patologia - HUAP, Universidade Federal Fluminense, CEP 24001-970, Niterói, RJ, Brazil
3Laboratório de Modelagem Molecular e QSAR (ModMolQSAR), Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, CEP 21941-590, Rio de Janeiro, RJ, Brazil

Received 2 May 2007; Accepted 16 July 2008

Copyright © 2011 Bruno L. Ferreira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. D. Lopez, C. D. Mathers, M. Ezzati, D. T. Jamison, and C. J. L. Murray, in Global Burden of Disease and Risk Factors, IBRD/The World Bank and Oxford University Press, Washington, DC, USA, 2006.
  2. World Health Organization, WHO, Department of Communicable Disease Surveillance, World Health Organization, Department of Essential Drugs and Medicines Policy, January 2007, http://www.who.int/en/.
  3. T. M. Barbosa and S. B. Levy, “The impact of antibiotic use on resistance development and persistence,” Drug Resistance Updates, vol. 3, no. 5, pp. 303–311, 2000. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Y. Ang, E. Ezike, and B. I. Asmar, “Antibacterial Resistance,” Indian Journal of Pediatrics, vol. 71, no. 3, pp. 229–239, 2004. View at Google Scholar · View at Scopus
  5. D. C. de Lima, P. Alvarez Abreu, C. C. de Freitas, D. O. Santos, R. O. Borges, T. C. Dos Santos et al., “Snake venom: any clue for antibiotics and CAM?” Evidence-Based Complementary and Alternative Medicine, vol. 2, pp. 39–47, 2005. View at Google Scholar
  6. L. Guardabassi and H. Kruse, “Overlooked aspects concerning development and spread of antimicrobial resistance,” Expert Review of Anti-Infective Therapy, vol. 1, no. 3, pp. 359–362, 2003. View at Google Scholar · View at Scopus
  7. K. L. Roos, “Emerging antimicrobial-resistant infections,” Archives of Neurology, vol. 61, pp. 1512–1514, 2004. View at Google Scholar
  8. J. White, “Bites and stings from venomous animals: a global overview,” Therapeutic Drug Monitoring, vol. 22, no. 1, pp. 65–68, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. D. C. Koh, A. Armugam, and K. Jeyaseelan, “Snake venom components and their applications in biomedicine,” Cellular and Molecular Life Sciences, vol. 63, pp. 3030–3041, 2006. View at Google Scholar
  10. S. H. Ferreira, D. C. Bartelt, and L. J. Greene, “Isolation of bradykinin-potentiating peptides from bothrops jararaca venom,” Biochemistry, vol. 9, no. 13, pp. 2583–2593, 1970. View at Google Scholar · View at Scopus
  11. G. L. Plosker and D. McTavish, “Captopril. A review of its pharmacology and therapeutic efficacy after myocardial infarction and in ischaemic heart disease,” Drugs & Aging, vol. 7, pp. 226–253, 1995. View at Google Scholar
  12. B. G. Stiles, F. W. Sexton, and S. A. Weinstein, “Antibacterial effects of different snake venoms: purification and characterization of antibacterial proteins from Pseudechis australis (Australian king brown or mulga snake) venom,” Toxicon, vol. 29, pp. 1129–1141, 1991. View at Google Scholar
  13. C. G. T. Oliveira, F. F. Miranda, V. F. Ferreira et al., “Synthesis and antimicrobial evaluation of 3-hydrazino-naphthoquinones as analogs of lapachol,” Journal of the Brazilian Chemical Society, vol. 12, no. 3, pp. 339–345, 2001. View at Google Scholar · View at Scopus
  14. A. L. Fuly, A. L. P. De Miranda, R. B. Zingali, and J. A. Guimarães, “Purification and characterization of a phospholipase A2 isoenzyme isolated from Lachesis muta snake venom,” Biochemical Pharmacology, vol. 63, no. 9, pp. 1589–1597, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. L. F. M. Izidoro, M. C. Ribeiro, G. R. L. Souza et al., “Biochemical and functional characterization of an l-amino acid oxidase isolated from Bothrops pirajai snake venom,” Bioorganic and Medicinal Chemistry, vol. 14, no. 20, pp. 7034–7043, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. R. G. Stábeli, S. Marcussi, G. B. Carlos et al., “Platelet aggregation and antibacterial effects of an l-amino acid oxidase purified from Bothrops alternatus snake venom,” Bioorganic and Medicinal Chemistry, vol. 12, no. 11, pp. 2881–2886, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. H. C. Castro, M. Fernandes, and R. B. Zingali, “Identification of bothrojaracin-like proteins in snake venoms from Bothrops species and Lachesis muta,” Toxicon, vol. 37, no. 10, pp. 1403–1416, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. S. R. Gill, D. E. Fouts, G. L. Archer et al., “Insights on evolution of virulence and resistance from the complete genome analysis of an early methicillin-resistant Staphylococcus aureus strain and a biofilm-producing methicillin-resistant Staphylococcus epidermidis strain,” Journal of Bacteriology, vol. 187, no. 7, pp. 2426–2438, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. M. M. Elrick, J. L. Walgren, M. D. Mitchell, and D. C. Thompson, “Proteomics: recent applications and new technologies,” Basic and Clinical Pharmacology and Toxicology, vol. 98, no. 5, pp. 432–441, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. D. W. Cushman and M. A. Ondetti, “History of the design of captopril and related inhibitors of angiotensin converting enzyme,” Hypertension, vol. 17, no. 4, pp. 589–592, 1991. View at Google Scholar · View at Scopus